| Title : COVID-19 and the nicotinic cholinergic system - Farsalinos_2020_Eur.Respir.J_56_ |
| Author(s) : Farsalinos K , Angelopoulou A , Alexandris N , Poulas K |
| Ref : Eur Respir J , 56 : , 2020 |
|
Abstract :
The prevalence of smoking among hospitalised COVID-19 patients is low. COVID-19 manifestations could be linked to impairment of the cholinergic anti-inflammatory pathway. Nicotinic cholinergic agonists should be examined as potential therapeutic options. https://bit.ly/2zfUZ1S |
| PubMedSearch : Farsalinos_2020_Eur.Respir.J_56_ |
| PubMedID: 32444400 |
Farsalinos K, Angelopoulou A, Alexandris N, Poulas K (2020)
COVID-19 and the nicotinic cholinergic system
Eur Respir J
56 :
Farsalinos K, Angelopoulou A, Alexandris N, Poulas K (2020)
Eur Respir J
56 :